Dai ichi Life Insurance Company Ltd Sells 6,261 Shares of Danaher Corporation $DHR

Dai ichi Life Insurance Company Ltd cut its holdings in shares of Danaher Corporation (NYSE:DHR) by 20.6% in the first quarter, Holdings Channel reports. The institutional investor owned 24,084 shares of the conglomerate’s stock after selling 6,261 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Danaher were worth $4,566,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of DHR. Enterprise Financial Services Corp boosted its holdings in Danaher by 1.4% in the 4th quarter. Enterprise Financial Services Corp now owns 3,219 shares of the conglomerate’s stock valued at $737,000 after purchasing an additional 46 shares during the period. Kennebec Savings Bank increased its holdings in shares of Danaher by 1.4% during the 4th quarter. Kennebec Savings Bank now owns 3,348 shares of the conglomerate’s stock worth $766,000 after purchasing an additional 46 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Danaher by 2.6% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,870 shares of the conglomerate’s stock valued at $428,000 after buying an additional 47 shares during the last quarter. High Note Wealth LLC raised its position in shares of Danaher by 19.2% during the fourth quarter. High Note Wealth LLC now owns 292 shares of the conglomerate’s stock valued at $67,000 after buying an additional 47 shares during the last quarter. Finally, First Command Advisory Services Inc. lifted its stake in shares of Danaher by 4.4% in the fourth quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock valued at $253,000 after buying an additional 47 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

NYSE:DHR opened at $191.87 on Friday. The firm has a market capitalization of $134.88 billion, a PE ratio of 34.08, a price-to-earnings-growth ratio of 2.38 and a beta of 0.79. The company has a quick ratio of 1.52, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The firm has a 50-day moving average price of $185.64 and a 200 day moving average price of $197.04.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the previous year, the business earned $0.77 earnings per share. The company’s quarterly revenue was up 5.5% on a year-over-year basis. Research analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.8%. Danaher’s payout ratio is currently 28.42%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Rothschild & Co Redburn set a $205.00 price target on Danaher in a research note on Friday, April 17th. Royal Bank Of Canada raised their price objective on Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a research report on Wednesday. Weiss Ratings raised Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, July 15th. Citigroup started coverage on Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $228.91.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.